Medical abortion for Australian women: It's time

Medical Journal of Australia

Volumn 183, Issue 7, 2005, Pages 378-380

  De Costa, Caroline M ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; MIFEPRISTONE; MISOPROSTOL; PROSTAGLANDIN DERIVATIVE;

ARTICLE; AUSTRALIA; CHINA; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ETHNIC GROUP; FEMALE; HEALTH CARE ACCESS; HUMAN; ISRAEL; NEW ZEALAND; NORTH AMERICA; PREGNANCY TERMINATION; RURAL AREA; RUSSIAN FEDERATION; THERAPEUTIC ABORTION; TUNISIA; TURKEY (REPUBLIC); UNITED KINGDOM; WESTERN EUROPE; WORLD HEALTH ORGANIZATION;

EID: 26444534407     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb07088.x     Document Type: Article

References (18)

1. American College of Obstetricians and Gynecologists. Recommendations on medical abortions issued to US obstetricians-gynecologists, 31 March 2001 [news release]. Available at: http://www.acog.org/from_home/publications/press_releases/ nr03-31-01-2.cfm (accessed Jun 2005).
2. Royal College of Obstetricians and Gynaecologists. National clinical guidelines. The care of women requesting induced abortion. London: RCOG, 2004.
3. Dickerson V, American College of Obstetricians and Gynecologists. ACOG letter on safety of RU-486, 7 December 2004 [news release]. Available at: http://www.acog.org/from_home/publications/press_releases/nr12-07-04.cfm (accessed Jun 2005).
4. Sparrow MJ. A woman's choice. Aust N Z J Obstet Gynaecol 2004; 44: 88-92.
5. Shannon CS, Winikoff B, Hausknecht R, et al. Multicenter trial of a simplified mifepristone medical abortion regimen. Obstet Gynecol 2005; 105: 345-351.
6. Schreiber CA, Creinin MD, Harwood B, Murthy AS. A pilot study of mifepristone and misoprostol administered at the same time for abortion in women with gestation from 50 to 63 days. Contraception 2005; 71: 447-450.
7. Faucher B, Baunot N, Madelenat P. The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked to the hospital: a prospective study of 433 patients. Gynecol Obstet Fertil 2005; 33: 220-227.
8. Hausknecht R. Mifeprex and misoprostol for early abortion: 4 1/2 years experience in the US. Presentation at the Annual Clinical Meeting of American College of Obstetricians and Gynecologists; 9 May 2005; San Francisco, Cal.
9. World Health Organization. Safe abortion: technical and policy guidance. Geneva: WHO, 2003.
10. Centers for Disease Control and Prevention (CDC). Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol - United States and Canada, 2001-2005. MMWR Morb Mortal Wkly Rep 2005; 54: 724.
11. Ashok PW, Flett GM, Templeton A. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol. Lancet 1998; 352: 542-543.
12. Baulieu EE. Contraception by the progesterone antagonist RU 486: a novel approach to human fertility control. Res Reprod 1987; 19: 3-4.
13. Hogan SF, Ireland K. Fatal acute spontaneous endometritis resulting from Clostridium sordelli. Am J Clin Pathol 1989; 91: 104-106.
14. McGregor JA, Soper DE, Lovell G, Todd JK. Maternal deaths associated with Clostridium sordellii infection. Am J Obstet Gynecol 1989; 161: 987-995.
15. Bartlett L, Berg C, Shulman H, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol 2004; 103: 729-737.
16. Gibson L. WHO puts abortifacients on its essential drugs list. BMJ 2005; 331: 68.
17. De Crespigny LJ, Savulescu J. Abortion: time to clarify Australia's confusing laws. Med J Aust 2004; 181: 201-203.
18. Chan A, Sage LC. Estimating Australia's abortion rates 1985-2003. Med J Aust 2005; 182: 447-452.